UY34048A - Proteínas de repetición enlazantes de il4/il13 y sus usos - Google Patents

Proteínas de repetición enlazantes de il4/il13 y sus usos

Info

Publication number
UY34048A
UY34048A UY0001034048A UY34048A UY34048A UY 34048 A UY34048 A UY 34048A UY 0001034048 A UY0001034048 A UY 0001034048A UY 34048 A UY34048 A UY 34048A UY 34048 A UY34048 A UY 34048A
Authority
UY
Uruguay
Prior art keywords
binding
repetition
proteins
inhibit
diseases
Prior art date
Application number
UY0001034048A
Other languages
English (en)
Inventor
Jacobs Steven
Karyn O'neil
Baumann Michael
Sennauser Gaby
Original Assignee
Janssen Biotech Inc
Molecular Partners
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Molecular Partners filed Critical Janssen Biotech Inc
Publication of UY34048A publication Critical patent/UY34048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Las proteínas de unión a IL4/IL13 comprenden dominios de unión, que inhiben la unión de IL4/IL13 a IL4Ralpaha y complejos de cadena gamma comunes (Tipo 1) s e inhiben la unión de IL4 a complejos de IL4Ralpha y IL13Ralphal (Tipo 2), y la unión de IL13 a IL13Ralphal y/o IL13Ralpha2, son útiles en el tratamiento de cáncer, enfermedades inflamatorias y otras enfermedades patológicas, tales como condiciones alérgicas o fibróticas, especialmente enfermedades pulmonares
UY0001034048A 2011-04-29 2012-04-30 Proteínas de repetición enlazantes de il4/il13 y sus usos UY34048A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481008P 2011-04-29 2011-04-29
US201161480999P 2011-04-29 2011-04-29
US201161481021P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
UY34048A true UY34048A (es) 2012-10-31

Family

ID=47068346

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034048A UY34048A (es) 2011-04-29 2012-04-30 Proteínas de repetición enlazantes de il4/il13 y sus usos

Country Status (14)

Country Link
US (2) US8722618B2 (es)
EP (1) EP2702069A4 (es)
JP (1) JP2014519808A (es)
KR (1) KR20140039203A (es)
CN (1) CN104105704A (es)
AR (1) AR086241A1 (es)
AU (1) AU2012249359A1 (es)
BR (1) BR112013027766A2 (es)
CA (1) CA2834624A1 (es)
EA (1) EA201391607A1 (es)
IL (1) IL229093A0 (es)
TW (1) TW201305337A (es)
UY (1) UY34048A (es)
WO (1) WO2012149439A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
ES2758352T3 (es) * 2010-11-26 2020-05-05 Molecular Partners Ag Proteínas de repetición diseñadas que se une a la seroalbúmina
AU2013283296A1 (en) * 2012-06-28 2015-02-05 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3004152B1 (en) * 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018195388A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
KR20200011685A (ko) * 2018-07-25 2020-02-04 주식회사유한양행 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
WO2020190852A2 (en) * 2019-03-17 2020-09-24 Jorge Fallas Topological control of receptor signaling using synthetic homo- and hetero-dimeric cytokine mimetics
MX2021014601A (es) * 2019-06-04 2022-02-11 Molecular Partners Ag Proteinas recombinantes de union a fap y su uso.
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
MX2022007122A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
CA3176845A1 (en) 2020-05-06 2021-11-11 Patrick AMSTUTZ Novel ankyrin repeat binding proteins and their uses
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
CN116789843A (zh) * 2022-03-16 2023-09-22 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
AU775997B2 (en) 1998-12-02 2004-08-19 Bristol-Myers Squibb Company DNA-protein fusions and uses thereof
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
CA2614512C (en) 2005-07-08 2014-01-07 University Of Zuerich Phage display using cotranslational translocation of fusion polypeptides
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
KR20090064559A (ko) 2006-10-16 2009-06-19 (주)제이슨알앤디 콘텐츠 부가정보를 전송하는 시스템 및 이용방법
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction

Also Published As

Publication number Publication date
KR20140039203A (ko) 2014-04-01
AR086241A1 (es) 2013-11-27
TW201305337A (zh) 2013-02-01
WO2012149439A2 (en) 2012-11-01
EP2702069A4 (en) 2015-04-29
US8722618B2 (en) 2014-05-13
JP2014519808A (ja) 2014-08-21
AU2012249359A1 (en) 2013-11-14
CA2834624A1 (en) 2012-11-01
US9206244B2 (en) 2015-12-08
CN104105704A (zh) 2014-10-15
BR112013027766A2 (pt) 2016-11-29
EP2702069A2 (en) 2014-03-05
EA201391607A1 (ru) 2014-04-30
IL229093A0 (en) 2013-12-31
US20140206599A1 (en) 2014-07-24
WO2012149439A3 (en) 2014-05-30
US20120277143A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
UY34048A (es) Proteínas de repetición enlazantes de il4/il13 y sus usos
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6710907A2 (es) Anticuerpos que se unen específicamente a cd33 que son útiles en el tratamiento de trastornos de células mieloides y del síndrome mielodisplásico (msd)
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
DOP2013000145A (es) Inmunoglobulinas de dominio variable dual biespecíficas de il-1 alfa y beta y su uso.
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1118859T1 (el) 6-αλκινυλο-πυριδινες ως μιμητες smac
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
GT201200314A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y de enfermedades inmunes y autoinmunes
EA201591767A8 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
IN2015DN02032A (es)
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112012020700A2 (pt) método de tratamento de paciente diagnosticadas com câncer do ovário kit de tratamento de cânce do ovario metodo de instrução a uma paciente humana com cãncer do ovario método promocionale comercial
CR20160285A (es) Inhibidores de quinasa relacionada con la tropomiosina (trk)
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
EA201390867A1 (ru) Композиции на основе глины и обножки, способ их получения и их применение в питании и терапевтическом лечении
DK3052109T3 (da) Terapi med celler fra human placenta og hematopoietiske celler